Antengene Signs Up to $1.9 Billion TCE Licensing Deal
BOSTON, Singapore and Hong Kong, June 22, 2026 Antengene Corporation Limited has announced a landmark strategic licensing agreement with...
solid tumors
Advertisement
Jazz and AbCellera Partner on Next-Gen Cancer Antibodies
DUBLIN, Ireland and VANCOUVER, British Columbia, June 17, 2026 Jazz Pharmaceuticals and AbCellera have announced a major strategic collaboration...
Niowave and Ratio Partner to Advance Actinium-225 Supply
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
Vivos Submits FDA IDE for RadioGel Therapy
KENNEWICK, Wash., June 5, 2026 Vivos Inc. announced the submission of an Early Feasibility Investigational Device Exemption (IDE) application...
OriCell’s Ori-C101 Advances to Phase II Trial in Liver Cancer
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
Advertisements
Oncolytics Reports Promising Pelareorep Data in RAS Cancers
SAN DIEGO, California, USA, June 1, 2026 Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with...
Greywolf Reports Durable Responses with First-in-Class ERAP1 Inhibitor
OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
Anaveon Reports Promising Phase 1 ANV600 Cancer Data at ASCO 2026
BASEL, Switzerland — May 28, 2026 Anaveon announced new clinical data from its Phase 1 EXPAND-1 trial showing encouraging...
Brenus Pharma Wins FDA IND Clearance for STC-1010
LYON, France — May 28, 2026 Brenus Pharma announced that the U.S. Food and Drug Administration has accepted the...
Advertisement
